Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia.
Department of Pharmacy Practice, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
Int J Health Plann Manage. 2019 Apr;34(2):e1200-e1207. doi: 10.1002/hpm.2758. Epub 2019 Feb 21.
A prospective observational study was carried out with the aim of evaluating the effectiveness of nasal continuous positive airway pressure (nCPAP) therapy on the health-related quality of life (QoL) of patients with obstructive sleep apnea (OSA).
The patients included in this study were those recently diagnosed with OSA (AHI > 5) and given nCPAP therapy, as well as being referred to a sleep laboratory for an assessment of their sleep disordered breathing. Prior to the start of nCPAP therapy and polysomnography evaluation, patients were asked to complete the validated Quebec sleep questionnaire (QSQ), and their baseline measurements were recorded.
Among the study population, 14.41% (n = 31) had mild OSA with an apnea and hypopnea index of 5 to 14.9 events/h, while 26.97% (n = 58) had moderate OSA and 40% (n = 86) had severe OSA. The overall average apnea and hypopnea index of the study population was 30.24 ± 9.73 events/h; mild OSA patients had an average apnea and hypopnea index of 10.09 ± 2.65 events/h, moderate OSA patients had 21.48 ± 4.40 events/h, and severe OSA patients had 59.16 ± 22.14 events/h. A significant difference was observed between the scores before treatment and after 6 months of therapy in all domains of the QSQ QoL scores (P < 0.0001).
Nasal continuous positive airway pressure treatment improved the QoL for patients with mild, moderate, and severe sleep apnea.
本前瞻性观察研究旨在评估经鼻持续气道正压通气(nCPAP)治疗对阻塞性睡眠呼吸暂停(OSA)患者健康相关生活质量(QoL)的影响。
本研究纳入的患者为近期诊断为 OSA(AHI>5)并接受 nCPAP 治疗的患者,以及因睡眠呼吸紊乱问题而被转至睡眠实验室评估的患者。在开始 nCPAP 治疗和多导睡眠图评估之前,患者需完成经验证的魁北克睡眠问卷(QSQ),并记录其基线测量值。
在研究人群中,轻度 OSA 患者占 14.41%(n=31),呼吸暂停低通气指数为 5 至 14.9 次/小时;中度 OSA 患者占 26.97%(n=58),重度 OSA 患者占 40%(n=86)。研究人群的平均呼吸暂停低通气指数为 30.24±9.73 次/小时;轻度 OSA 患者的平均呼吸暂停低通气指数为 10.09±2.65 次/小时,中度 OSA 患者为 21.48±4.40 次/小时,重度 OSA 患者为 59.16±22.14 次/小时。所有 QSQ 生活质量评分的各个领域在治疗前与治疗 6 个月后的评分均存在显著差异(P<0.0001)。
经鼻持续气道正压通气治疗改善了轻度、中度和重度睡眠呼吸暂停患者的生活质量。